TYMP and breast cancer: Researchers found derivatives (80) and (81) with the highest potency against breast cancer cell line (MCF-7), as well as thymidine phosphorylase enzyme inhibitory activity, as compared to the reference drugs adriamycin and 7-deazaxanthin, respectively [103].